Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX1 | P51575 | 4/20 | 0.75 |
| ▸ | P2RX3 | P56373 | 4/20 | 0.75 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.75 |
| ▸ | P2RY1 | P47900 | 7/20 | 0.73 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.73 |
| ▸ | SRC | P12931 | 2/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.73 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.73 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.70 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.69 |
| ▸ | TRPM2 | O94759 | 2/20 | 0.69 |
| ▸ | MACROD2 | A1Z1Q3 | 1/20 | 0.69 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.69 |
| ▸ | MACROD1 | Q9BQ69 | 1/20 | 0.69 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.65 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.65 |
| ▸ | LDHA | P00338 | 1/20 | 0.65 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.65 |
| ▸ | FBP1 | P09467 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18771184 | 1.00 | P2RX1 (0.75) | P2RX1P2RX3P2RX2P2RY1P2RY2 | |
| SCHEMBL29750562 | 1.00 | P2RX1 (0.75) | P2RX1P2RX3P2RX2P2RY1P2RY2 | |
| SCHEMBL20820229 | 1.00 | P2RX1 (0.75) | P2RX1P2RX3P2RX2P2RY1P2RY2 | |
| SCHEMBL15703927 | 0.93 | P2RY1 (0.73) | P2RX1P2RX3P2RX2P2RY1P2RY2 | |
| SCHEMBL18771186 | 0.93 | P2RY1 (0.73) | P2RX1P2RX3P2RX2P2RY1P2RY2 | |
| SCHEMBL12961954 | 0.90 | P2RX1 (0.78) | P2RX1P2RX3P2RX2P2RY1P2RY2 | |
| SCHEMBL20820163 | 0.89 | P2RY1 (0.63) | P2RX1P2RX3P2RX2P2RY1P2RY2 | |
| SCHEMBL16081092 | 0.89 | P2RY1 (0.63) | P2RX1P2RX3P2RX2P2RY1P2RY2 | |
| Adenosine Triphosphate SCHEMBL4362224 | 0.88 | P2RY1 (0.94) | P2RX1P2RX3P2RX2P2RY1P2RY2 | |
| Adenosine Triphosphate SCHEMBL20550531 | 0.88 | P2RY1 (0.94) | P2RX1P2RX3P2RX2P2RY1P2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220145295-A1 | ENZYMATIC RNA SYNTHESIS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-05-12 | — | — | US | claimed |
| EP-3864151-A2 | ENZYMATIC RNA SYNTHESIS | President and Fellows of Harvard College (US) | 2021-08-18 | — | — | EP | claimed |
| US-20210052706-A1 | COMPOSITIONS AND METHODS FOR FACILITATING DELIVERY OF SYNTHETIC NUCLEIC ACIDS TO CELLS | TRANSLATE BIO MA, INC. (US) | 2021-02-25 | — | — | US | claimed |
| EP-3737424-A1 | COMPOSITIONS AND METHODS FOR FACILITATING DELIVERY OF SYNTHETIC NUCLEIC ACIDS TO CELLS | Translate Bio MA, Inc. (US) | 2020-11-18 | — | — | EP | claimed |
| US-20180311176-A1 | NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACID COMPLEXES | TRANSLATE BIO MA, INC. (US) | 2018-11-01 | — | — | US | claimed |
| EP-3368089-A1 | NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACID COMPLEXES | TRANSLATE BIO MA, INC. (US) | 2018-09-05 | — | — | EP | claimed |
| WO-2017075038-A1 | NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACID COMPLEXES | RANA THERAPEUTICS, INC. (US) | 2017-05-04 | — | — | WO | claimed |
| EP-3033424-A1 | COMPOSITIONS AND METHODS FOR MODULATING RNA | Rana Therapeutics, Inc. (US) | 2016-06-22 | — | — | EP | claimed |
| WO-2015023975-A1 | COMPOSITIONS AND METHODS FOR MODULATING RNA | RANA THERAPEUTICS, INC. (US) | 2015-02-19 | — | — | WO | claimed |
| US-20140170689-A1 | Modified Diguanylate Cyclase-Phosphodiesterase and Method for Enzymatic Production of Cyclic-diGMP | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2014-06-19 | — | — | US | claimed |
| EP-2451980-B1 | CHEMICALLY MODIFIED LIGASE COFACTORS, DONORS AND ACCEPTORS | TRILINK BIOTECHNOLOGIES (US) | 2014-05-21 | — | — | EP | claimed |
| US-8728725-B2 | Chemically modified ligase cofactors, donors and acceptors | TRILINK BIOTECHNOLOGIES (US) | 2014-05-20 | — | — | US | claimed |
| US-20260138999-A1 | REAGENTS AND THEIR USE FOR MODULAR ENANTIODIVERGENT SYNTHESIS OF C-P BONDS | BRISTOL MYERS SQUIBB CO (US) | 2026-05-21 | — | — | US | disclosed |
| US-12545900-B2 | CGAS/DNCV-like nucleotidyltransferases and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2026-02-10 | — | — | US | disclosed |
| US-12492217-B2 | Reagents and their use for modular enantiodivergent synthesis of C—P bonds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-12-09 | — | — | US | disclosed |
| US-20250360089-A1 | NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACID COMPLEXES | TRANSLATE BIO MA, INC. (US) | 2025-11-27 | — | — | US | disclosed |
| WO-2014160484-A1 | AMINO ACID PHOSPHORAMIDATE PRONUCLEOTIDES OF 2'-CYANO, AZIDO AND AMINO NUCLEOSIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS, INC. (US) | 2014-10-02 | — | — | WO | disclosed |
| US-20140271547-A1 | AMINO ACID PHOSPHORAMIDATE PRONUCLEOTIDES OF 2'-CYANO, AZIDO AND AMINO NUCLEOSIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS, INC. | 2014-09-18 | — | — | US | disclosed |
| US-20140271547-A1 | AMINO ACID PHOSPHORAMIDATE PRONUCLEOTIDES OF 2'-CYANO, AZIDO AND AMINO NUCLEOSIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS, INC. | 2014-09-18 | — | — | US | disclosed |
| US-20140170689-A1 | Modified Diguanylate Cyclase-Phosphodiesterase and Method for Enzymatic Production of Cyclic-diGMP | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2014-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260138999-A1 | REAGENTS AND THEIR USE FOR MODULAR ENANTIODIVERGENT SYNTHESIS OF C-P BONDS | RNGTT, CDA, DCTD | P2RX1 1240/4885P2RX3 1431/4885P2RX2 1490/4885 |
| US-20180311176-A1 | NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACID COMPLEXES | DIS3, SYNCRIP, EXOSC5 | P2RX1 4598/4885P2RX3 4577/4885P2RX2 4724/4885 |
| US-20250360089-A1 | NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACID COMPLEXES | DIS3, SYNCRIP, EXOSC5 | P2RX1 4598/4885P2RX3 4577/4885P2RX2 4724/4885 |
| US-20210052706-A1 | COMPOSITIONS AND METHODS FOR FACILITATING DELIVERY OF SYNTHETIC NUCLEIC ACIDS TO CELLS | NSUN3, RNGTT, CSGALNACT1 | P2RX1 4858/4885P2RX3 4846/4885P2RX2 4852/4885 |
| US-20140271547-A1 | AMINO ACID PHOSPHORAMIDATE PRONUCLEOTIDES OF 2'-CYANO, AZIDO AND AMINO NUCLEOSIDES FOR THE TREATMENT OF HCV | PNP, RNGTT, NSUN2 | P2RX1 84/4885P2RX3 144/4885P2RX2 185/4885 |
| US-12492217-B2 | Reagents and their use for modular enantiodivergent synthesis of C—P bonds | PNKP, POLL, RNGTT | P2RX1 2268/4885P2RX3 2326/4885P2RX2 2022/4885 |
| US-12545900-B2 | CGAS/DNCV-like nucleotidyltransferases and uses thereof | NT5C2, NT5DC2, NTPCR | P2RX1 223/4885P2RX3 304/4885P2RX2 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.